MDMA/citalopram
MDMA/citalopram is a combination of the entactogen and monoamine releasing agent 3,4-methylenedioxymethamphetamine (MDMA; also known as midomafetamine or "ecstasy") and the selective serotonin reuptake inhibitor (SSRI) citalopram which is under development for the treatment of post-traumatic stress disorder (PTSD). Citalopram is taken after MDMA in the combination, and its inclusion is intended to help reduce the well-known negative after-effects of MDMA such as temporarily worsened mood (sometimes referred to colloquially as "Blue Mondays").